Exascale Labs Holdings Inc. has announced the appointment of Jake Carney as its new Chief Financial Officer (CFO), effective September 25, 2026. This leadership change is significant as it comes during a period of growth for the company in the prepackaged software industry.
Exascale Labs Holdings Inc. operates under the SIC code 7372, which pertains to Services-Prepackaged Software. The company is publicly traded on the Nasdaq under the ticker symbols XLAB and XLABW. Its recent filings indicate a focus on enhancing its financial leadership and operational strategies.
The latest SEC filing details that Gildas Bonnier has stepped down as Interim CFO, allowing for Carney's appointment. Bonnier's departure was not due to any disagreements regarding company operations, policies, or practices. Instead, it marks the completion of a formal search process for a permanent CFO.
Carney brings extensive experience to his new role, having previously served as CFO of ARC Group Securities Acquisition I and Deal Flow Capital. His background includes significant roles in banking, investment advisory, and fintech environments. The company has entered into an employment agreement with Carney, which includes a base salary of $6,000 per month and eligibility for employee benefits.
This leadership transition may influence various stakeholders, including investors, employees, and competitors in the prepackaged software sector. Exascale Labs is categorized as an emerging growth company, which subjects it to reduced public company reporting requirements.
Looking ahead, the filing does not specify what will happen next regarding the company's strategic direction or any upcoming filings. However, the appointment of a new CFO typically signals a renewed focus on financial management and operational efficiency, which could be crucial for Exascale Labs as it seeks to strengthen its position in the competitive landscape.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










